Based on the remarkable similarity in the fusion mechanism between the CoV S protein and envelope glycoproteins in HIV-1, we discovered a series of pan-CoV fusion inhibitors, which also show potent inhibition against recently identified COVID-19 variants, including those identified in the UK (Alpha), South Africa (Beta), and India (Delta). This evidence concerns the gene PROS1 and COVID-19.